ANP (Atrial Natriuretic Peptide) vs TB-500
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →TB-500
Thymosin Beta-4 (TB-500) is a naturally occurring peptide present in almost all human and animal cells. It plays a crucial role in tissue repair and regeneration.
Full details →Side-by-Side Comparison
| Aspect | ANP (Atrial Natriuretic Peptide) | TB-500 |
|---|---|---|
| Mechanism | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. | TB-500 promotes cell migration and differentiation, regulates actin (a cell-building protein), and reduces inflammation. It supports the formation of new blood vessels and wound healing. |
| Typical Dosage | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. | Research protocols typically use 2-2.5mg twice weekly during the loading phase, followed by maintenance dosing of 2mg every 2 weeks. |
| Administration | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. | Administered via subcutaneous or intramuscular injection. Some protocols suggest injection near injury sites. |
| Side Effects | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. | May cause temporary fatigue, headache, or localized irritation at injection sites. |
| Best For |
What They Have in Common
Both ANP (Atrial Natriuretic Peptide) and TB-500 are commonly used for: